Lipopolysaccharide- TLR-4 Axis regulates Osteoclastogenesis independent of RANKL/RANK signaling
Date
2021-03-25Journal
BMC ImmunologyPublisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
Background: Lipopolysaccharide (LPS) is an endotoxin and a vital component of gram-negative bacteria’s outer membrane. During gram-negative bacterial sepsis, LPS regulates osteoclast differentiation and activity, in addition to increasing inflammation. This study aimed to investigate how LPS regulates osteoclast differentiation of RAW 264.7 cells in vitro. Results: Herein, we revealed that RAW cells failed to differentiate into mature osteoclasts in vitro in the presence of LPS. However, differentiation occurred in cells primed with receptor activator of nuclear factor-kappa-Β ligand (RANKL) for 24 h and then treated with LPS for 48 h (henceforth, denoted as LPS-treated cells). In cells treated with either RANKL or LPS, an increase in membrane levels of toll-like receptor 4 (TLR4) receptor was observed. Mechanistically, an inhibitor of TLR4 (TAK-242) reduced the number of osteoclasts as well as the secretion of tumor necrosis factor (TNF)-α in LPS-treated cells. RANKL-induced RAW cells secreted a very basal level TNF-α. TAK-242 did not affect RANKL-induced osteoclastogenesis. Increased osteoclast differentiation in LPS-treated osteoclasts was not associated with the RANKL/RANK/OPG axis but connected with the LPS/TLR4/TNF-α tumor necrosis factor receptor (TNFR)-2 axis. We postulate that this is because TAK-242 and a TNF-α antibody suppress osteoclast differentiation. Furthermore, an antibody against TNF-α reduced membrane levels of TNFR-2. Secreted TNF-α appears to function as an autocrine/ paracrine factor in the induction of osteoclastogenesis independent of RANKL. Conclusion: TNF-α secreted via LPS/TLR4 signaling regulates osteoclastogenesis in macrophages primed with RANKL and then treated with LPS. Our findings suggest that TLR4/TNF-α might be a potential target to suppress bone loss associated with inflammatory bone diseases, including periodontitis, rheumatoid arthritis, and osteoporosis. Copyright 2021, The Author(s).Sponsors
Dr. Joseph Mauban at Confocal Microscopy Core at the University of Maryland, Baltimore School of Medicine, is gratefully acknowledged for providing technical help using the Nikon Scanning Disk Microscope.Identifier to cite or link to this item
http://hdl.handle.net/10713/15172ae974a485f413a2113503eed53cd6c53
10.1186/s12865-021-00409-9
Scopus Count
Collections
Related articles
- Dual modulation of osteoclast differentiation by lipopolysaccharide.
- Authors: Zou W, Bar-Shavit Z
- Issue date: 2002 Jul
- Aminothiazoles inhibit RANKL- and LPS-mediated osteoclastogenesis and PGE2 production in RAW 264.7 cells.
- Authors: Kats A, Norgård M, Wondimu Z, Koro C, Concha Quezada H, Andersson G, Yucel-Lindberg T
- Issue date: 2016 Jun
- Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
- Authors: Wada N, Maeda H, Yoshimine Y, Akamine A
- Issue date: 2004 Sep
- Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
- Authors: Hayashi S, Tsuneto M, Yamada T, Nose M, Yoshino M, Shultz LD, Yamazaki H
- Issue date: 2004 Jun
- Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
- Authors: Yang S, Takahashi N, Yamashita T, Sato N, Takahashi M, Mogi M, Uematsu T, Kobayashi Y, Nakamichi Y, Takeda K, Akira S, Takada H, Udagawa N, Furusawa K
- Issue date: 2005 Aug 1